| Tchem | B-cell receptor CD22 |
Mediates B-cell B-cell interactions. May be involved in the localization of B-cells in lymphoid tissues. Binds sialylated glycoproteins; one of which is CD45. Preferentially binds to alpha-2,6-linked sialic acid. The sialic acid recognition site can be masked by cis interactions with sialic acids on the same cell surface. Upon ligand induced tyrosine phosphorylation in the immune response seems to be involved in regulation of B-cell antigen receptor signaling. Plays a role in positive regulation through interaction with Src family tyrosine kinases and may also act as an inhibitory receptor by recruiting cytoplasmic phosphatases via their SH2 domains that block signal transduction through dephosphorylation of signaling molecules.
Comments
| Disease | Target Count | P-value |
|---|---|---|
| osteosarcoma | 7933 | 1.65250372683426E-7 |
| posterior fossa group B ependymoma | 1530 | 2.79527712369873E-6 |
| Pick disease | 1893 | 1.6212450497905E-4 |
| primary Sjogren syndrome | 789 | 2.23784301702872E-4 |
| nasopharyngeal carcinoma | 1056 | 2.74043157920254E-4 |
| psoriasis | 6685 | 6.08442670553732E-4 |
| group 4 medulloblastoma | 1875 | 0.00412035429990923 |
| chronic lymphosyte leukemia | 232 | 0.00414041315696697 |
| adult high grade glioma | 2148 | 0.00961166474812127 |
| progressive supranuclear palsy | 674 | 0.0101674218973994 |
| interstitial cystitis | 2299 | 0.011130386690255 |
| cutaneous lupus erythematosus | 1056 | 0.0199932155027177 |
| Disease | log2 FC | p |
|---|---|---|
| chronic lymphosyte leukemia | -1.200 | 0.004 |
| cutaneous lupus erythematosus | 2.400 | 0.020 |
| psoriasis | 1.100 | 0.001 |
| osteosarcoma | -2.953 | 0.000 |
| group 4 medulloblastoma | -1.300 | 0.004 |
| interstitial cystitis | 1.600 | 0.011 |
| adult high grade glioma | -1.200 | 0.010 |
| posterior fossa group B ependymoma | -1.200 | 0.000 |
| primary Sjogren syndrome | 1.200 | 0.000 |
| nasopharyngeal carcinoma | -1.400 | 0.000 |
| Pick disease | -1.500 | 0.000 |
| progressive supranuclear palsy | -1.300 | 0.010 |
| Species | Source |
|---|---|
| Chimp | OMA EggNOG |
| Macaque | OMA EggNOG |
| Mouse | OMA Inparanoid |
| Rat | OMA Inparanoid |
| Dog | OMA EggNOG Inparanoid |
| Horse | OMA EggNOG Inparanoid |
| Cow | OMA EggNOG |
| Opossum | OMA EggNOG Inparanoid |
CHEMBL502788
pIC50 6.00
CHEMBL501599
pIC50 6.05
CHEMBL509633
pIC50 6.33
CHEMBL509768
pIC50 6.40
CHEMBL502862
pIC50 6.62
CHEMBL511111
pIC50 6.64
| PMID | Text |
|---|---|
| 26507663 | results demonstrate that loss of high affinity CD22 ligands on GC B-cells occurs in both mice and humans through alternative mechanisms, unmasking CD22 relative to naive and memory B-cells |
| 26379425 | Anti-CD22-magnetic nanoparticles-doxorubicin inhibited the proliferation of Raji cells, significantly increased the uptake of doxorubicin, and induced apoptosis. |
| 26017478 | MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis. |
| 25484043 | These results suggest that the in vivo mechanism of non-ligand-blocking epratuzumab may, in part, involve the unmasking of CD22 to facilitate the trans-interaction of B cells with vascular endothelium. |
| 25182044 | By using integrative genomics and analysing the relationships of COPD phenotypes with SNPs and gene expression in lung tissue, we identified CST3 and CD22 as potential causal genes for airflow obstruction. |
| 23184497 | study detected the expression of CD22 and CD72 on B cells of myasthenia gravis, compared to multiple sclerosis patient controls and healthy controls y |
| 23083346 | In the absence of functional CD22, B cells have a "hyperactivated" phenotype, CD22 dysfunction could contribute to the pathogenesis of autoimmune diseases. (Review) |
| 22986740 | The finding that CD22 is expressed on lung cancer cells is significant in revealing a heretofore unknown mechanism of tumorigenesis and metastasis |
| 22355053 | Anti-CD22 recombinant immunotoxin moxetumomab pasudotox has activity in relapsed/refractory hairy cell leukemia. |
| 22017452 | Our study implicates the CD22DeltaE12 genetic defect in the aggressive biology of relapsed or therapy-refractory paediatric B-lineage ALL. |
| More... |
MHLLGPWLLLLVLEYLAFSDSSKWVFEHPETLYAWEGACVWIPCTYRALDGDLESFILFHNPEYNKNTSK 1 - 70 FDGTRLYESTKDGKVPSEQKRVQFLGDKNKNCTLSIHPVHLNDSGQLGLRMESKTEKWMERIHLNVSERP 71 - 140 FPPHIQLPPEIQESQEVTLTCLLNFSCYGYPIQLQWLLEGVPMRQAAVTSTSLTIKSVFTRSELKFSPQW 141 - 210 SHHGKIVTCQLQDADGKFLSNDTVQLNVKHTPKLEIKVTPSDAIVREGDSVTMTCEVSSSNPEYTTVSWL 211 - 280 KDGTSLKKQNTFTLNLREVTKDQSGKYCCQVSNDVGPGRSEEVFLQVQYAPEPSTVQILHSPAVEGSQVE 281 - 350 FLCMSLANPLPTNYTWYHNGKEMQGRTEEKVHIPKILPWHAGTYSCVAENILGTGQRGPGAELDVQYPPK 351 - 420 KVTTVIQNPMPIREGDTVTLSCNYNSSNPSVTRYEWKPHGAWEEPSLGVLKIQNVGWDNTTIACAACNSW 421 - 490 CSWASPVALNVQYAPRDVRVRKIKPLSEIHSGNSVSLQCDFSSSHPKEVQFFWEKNGRLLGKESQLNFDS 491 - 560 ISPEDAGSYSCWVNNSIGQTASKAWTLEVLYAPRRLRVSMSPGDQVMEGKSATLTCESDANPPVSHYTWF 561 - 630 DWNNQSLPYHSQKLRLEPVKVQHSGAYWCQGTNSVGKGRSPLSTLTVYYSPETIGRRVAVGLGSCLAILI 631 - 700 LAICGLKLQRRWKRTQSQQGLQENSSGQSFFVRNKKVRRAPLSEGPHSLGCYNPMMEDGISYTTLRFPEM 701 - 770 NIPRTGDAESSEMQRPPPDCDDTVTYSALHKRQVGDYENVIPDFPEDEGIHYSELIQFGVGERPQAQENV 771 - 840 DYVILKH 841 - 847 //
| PMID | Year | Title |
|---|---|---|
| 26507663 | 2015 | Unmasking of CD22 Co-receptor on Germinal Center B-cells Occurs by Alternative Mechanisms in Mouse and Man. |
| 26379425 | 2015 | Novel synthesizing method of pH-dependent doxorubicin-loaded anti-CD22-labelled drug delivery nanosystem. |
| 26017478 | 2015 | MicroRNA-19a and CD22 Comprise a Feedback Loop for B Cell Response in Sepsis. |
| 25484043 | 2015 | Extensive crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in human lymphoma cells. |
| 25218447 | 2014 | Uncovering global SUMOylation signaling networks in a site-specific manner. |
| 25182044 | 2014 | Genetic regulation of gene expression in the lung identifies CST3 and CD22 as potential causal genes for airflow obstruction. |
| 23184497 | 2013 | Modulation of B cell regulatory molecules CD22 and CD72 in myasthenia gravis and multiple sclerosis. |
| 23083346 | 2012 | CD22 and autoimmune disease. |
| 22986740 | 2012 | CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. |
| 22355053 | 2012 | Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. |
| More... |
